COmpARATIVE EFFECTIVENESS RESEARCH OUR SOLUTION
offer the largest convenience sample available in proprietary databases
great potential for improving healthcare
hard evidence to inform choices. The Truven Health AnalyticsSM MarketScan®
Retrospective Analyses of Outcomes
longitudinal, patient-level analyses of health and economic outcomes.
Comprehensive Data to Support Comparative Effectiveness Studies
different options that are available for
treating a particular medical condition,
§ Cost effectiveness of drugs and other
§ Effectiveness of brand versus generic
Specific patient population Studies Figure 1: Age Comparison Evaluation of Treatment Featured peer-Reviewed Effectiveness Over Time publications
physician office visits, hospitalizations,
of these data sources allows researchers
on treatment effectiveness over time. On behalf of the Assistant Secretary for Planning and Evaluation (ASPE), Truven Health is creating Web-based tools to facilitate comparative effectiveness research using multiple databases, including MarketScan data.
Amin AN, Lin J, Johnson BH, Schulman KL. Clinical and economic
2009; Nov 18; [Epub ahead of print].
Current Medical Research and Opinion 2008 Aug; 24(8): 2203-17. [Cohen
Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and
risk of venous thromboembolism receiving appropriate enoxaparin or
surgical patients. Health Services Research 2008; 43(6): 2067–85.
Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on
Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Healthcare
Brixner DI, Lenhart G, Young DC,
Chu E, Schulman KL, Zelt S, Song X. Mark TL, Gibson T, McGuigan K. The
effects of antihypertensive step-therapy
Citrome L, Reist C, Palmer L, Montejano LB, Lenhart G, Cuffel B,
T, Mark TL, Del Valle M. Comparison
Rugo HS, Kohles J, Schulman KL. Cost
Wish JB, Nassar GM, Schulman K, del
patients with chronic kidney disease. Clinical Nephrology 2008; 69(4): 251–9. Song X, Long SR, Marder WD, Sullivan SD, Kallich J. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Annals of Pharmacotherapy 2009; 43(7): 1203–10.
Wang MT, Skrepnek GH, Armstrong E, Sherrill DL, Harris RB, Tsai CL, Malone DC. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Current Medical Research and Opinion 2008; 24(3): 859–67. FOR mORE INFORmATION To learn how our research and information solutions can support your comparative effectiveness analyses, please contact us at +1 866 301 5419 or [email protected] ABOUT TRUVEN HEALTH ANALYTICS
Truven Health Analytics delivers unbiased information, analytic tools, benchmarks, and services to the healthcare industry. Hospitals, government agencies, employers, health plans, clinicians, pharmaceutical, and medical device companies have relied on us for more than 30 years. We combine our deep clinical, financial, and healthcare management expertise with innovative technology platforms and information assets to make healthcare better by collaborating with our customers to uncover and realize opportunities for improving quality, efficiency, and outcomes. With more than 2,000 employees globally, we have major offices in Ann Arbor, Mich.; Chicago; and Denver. Advantage Suite, Micromedex, ActionOI, MarketScan, and 100 Top Hospitals are registered trademarks or trademarks of Truven Health Analytics.
truvenhealth.com | 1.800.525.90832012 Truven Health Analytics Inc. All rights reserved. All other product names used herein are trademarks of their respective owners. ACRS 11228 0912
GLOBALIZATION: WHAT IS NEW; EFFECTIVE GLOBAL Marketing Department, Bloomsburg University, Pennsylvania, Distinguished Professor Emeritus of Marketing and International Business, Concordia University, Montreal, and Distinguished Visiting Professor International Business, Helsinki Professor of International Business, Helsinki School of Economics Abstract What is new and important about glob
PROPOSITION 65 STATUS REPORT SAFE HARBOR LEVELS: January 2005 Office of Environmental Health Hazard Assessment California Environmental Protection Agency The energy challenge facing California is real. Every Californian needs to take immediate action to reduce energy consumption. TABLE OF CONTENTS Proposition 65 Safe Harbor Levels Development …………………